Vol. 4 No. 2 (2024)
Reimbursement Reviews

Polatuzumab Vedotin (Polivy)

decorative image of the issue cover

Published February 27, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses polatuzumab vedotin (Polivy), 30 mg or 140 mg single-use vial, lyophilized powder for solution for IV infusion.
  • Indication: Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone, indicated for the treatment of adult patients with previously untreated large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, Epstein-Barr virus-positive diffuse large B-cell lymphoma not otherwise specified, and T-cell/histiocyte-rich large B-cell lymphoma.